← Back to Clinical Trials
Recruiting NCT06013579

NCT06013579 Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06013579
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition HIV Infections
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2023-08-01
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Phase 1 Gym Exercise HIITPhase 1 Gym Exercise CMEPhase 2 Home Exercise Coaching Text Messages

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2023-08-01 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

People aging with HIV are at higher risk for Alzheimer's disease and related dementias, and although physical activity is a promising target to mitigate such risk, this population engages in low levels of physical activity. Few studies have tested cognitive effects of exercise interventions or examined mechanisms of adherence to long-term exercise among diverse samples of midlife and older people with HIV. The current study will leverage an existing R01 to address these gaps and provide implications for development of personalized approaches for the treatment and prevention of cognitive impairment and dementia in older people with HIV.

Eligibility Criteria

Inclusion Criteria: * Confirmed HIV * Sedentary lifestyle, defined as self-reported PA that breaks a sweat \<3 days/week, with no regular resistance exercise for 3 months preceding study; * Fatigued (≥2.0 on either of the first two screening items on the HIV-Related Fatigue Scale) * On a current, contemporary ART regimen for \>=12 months; * HIV-1 RNA \<200 copies/mL in the past 12 months (assessed via medical records) * Willing to engage in a supervised exercise program 3 times/week for 4 months * Cell phone or email to accept messages * Weight \<450 lbs * Medical clearance by study healthcare professional Exclusion Criteria: * Weight over 450 pounds * Use of sex hormone therapy, if on for ≤3 months (stable doses for \>3 months will be permitted) * Use of other hormone replacement, if on for ≤ 3 months (stable doses \>3 months will be permitted) * Anemia (Hemoglobin ≤9 g/dL for women or ≤10 g/dL for men) due to contribution to fatigue, * Diagnosis of mitochondrial disease, * Active substance abuse or other factors that could prevent compliance or safety with study visits, at the discretion of the site investigator, * Reasons for medical exclusion, as determined by Nurse Practioner: 1. Uncontrolled hypertension defined as resting systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg; participants who do not meet these criteria at first screening will be reevaluated, including follow-up evaluation by their primary care provider with initiation or adjustment of anti-hypertensive medications, 2. Unstable ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test without negative follow-up evaluation will be cause for exclusion; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist, 3. New York Heart Association Class III or IV congestive heart failure, clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia, 4. Pulmonary disease requiring the use of supplemental oxygen at rest or with physical exertion, 5. Malignancy requiring chemotherapy or radiation therapy within 24 weeks prior to enrollment, 6. Poorly controlled diabetes, as evidenced by hemoglobin A1c \> 8.5, documented within 6 months of study visit or current use of insulin, 7. Surgery/trauma/injury/fracture within 24 weeks prior to enrollment that, in the opinion of the study clinician, may impact a subject's baseline functional testing and ability to exercise, 8. Balance impairments that may impact functional testing and ability to safely exercise as reported by the participant or in their medical record, 9. Orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made), 10. Persons who, in the judgment of the study clinician, appear to have unstable health or are incapable of safely participating in the exercise intervention.

Contact & Investigator

Central Contact

Pariya Wheeler, PhD

✉ plfazeli@uab.edu

📞 205-996-0330

Frequently Asked Questions

Who can join the NCT06013579 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06013579 currently recruiting?

Yes, NCT06013579 is actively recruiting participants. Contact the research team at plfazeli@uab.edu for enrollment information.

Where is the NCT06013579 trial being conducted?

This trial is being conducted at Birmingham, United States, Aurora, United States, Seattle, United States.

Who is sponsoring the NCT06013579 clinical trial?

NCT06013579 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 110 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology